ANDA Avalanche: How Will FDA Deal With The 600 Received This Month?
Executive Summary
Experts say one idea may be to borrow some new drug staff to help relieve the pressure; FDA says it will use all available resources.
You may also be interested in...
Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.
Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.